sirexatamab
Generic: DKN-01·Code: DKN-01
sirexatamab: developed by 1 company · 1 clinical trial tracked.
sirexatamab evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect sirexatamab to CYPH; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could sirexatamab → CYPH affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | Phase 2 |
Clinical Trials (1)
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Primary endpoint: ). Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
InterventionalRandomizedopen8 targetStarted 2023-08Completion 2029-011 site · United StatesM.D. Anderson Cancer Center
Frequently asked questions
Who is developing sirexatamab?
sirexatamab is being developed by CYPHERPUNK TECHNOLOGIES INC..
How many clinical trials involve sirexatamab?
BioSniper tracks 1 clinical trial involving sirexatamab.